Related Experiment Video
Updated: May 12, 2025

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
Kimberly Perez1, Jaydira Del Rivero2, Erin B Kennedy3
1Dana-Farber Cancer Institute, Boston, MA.
Purpose:
To develop a clinical practice guideline and recommendations for symptom management of patients with well-differentiated grade 1 to grade 3 metastatic gastroenteropancreatic neuroendocrine tumors.
Methods:
ASCO convened an Expert Panel to develop a clinical practice guideline by reviewing the literature for relevant guidelines, systematic reviews, randomized controlled trials (RCTs), and observational studies to develop recommendations for clinical practice.
Results:
The literature review identified eight guidelines, 19 systematic reviews, and three RCTs that informed the development of guideline recommendations.
Recommendations:
Recommendations are included for carcinoid syndrome, carcinoid heart disease and carcinoid crisis, and functional pancreatic neuroendocrine tumor syndromes. Recommendations are provided for surgical management, liver-directed therapy, and systemic therapy options, as well as palliative care. Limited guidance is provided for sequencing of interventions.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Acute Pancreatitis II: Clinical Manifestations and Management
Irritable Bowel Syndrome III: Medical and Nursing Management
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

